US EditionMerck to invest $1 billion in U.S. drug manufacturing plant
- Merck announced on April 29, 2025, a $1 billion investment to build a drug manufacturing plant in Wilmington, Delaware.
- This investment follows Merck’s broader strategy to expand U.S. Manufacturing, partly influenced by recent tariffs and reshoring efforts.
- The new 470,000-square-foot biologics center will create about 500 full-time jobs and 4,000 construction jobs, focusing on producing Keytruda cancer treatments.
- Keytruda generated $29.5 billion in 2024 sales and accounts for nearly half of Merck’s revenue, making domestic production critical for supply security, said CEO Robert M. Davis.
- The facility will be operational by 2028, bolster U.S. Biotech growth, and signal Merck’s ongoing commitment to domestic manufacturing and job creation.
17 Articles
17 Articles
Merck breaks ground on $1B Delaware site to boost US supply chain
Thousands of jobs could be on the horizon for American workers as drug manufacturer Merck takes steps to move manufacturing into the U.S., particularly in the form of a $1 billion state-of-the-art biologics center under construction in Wilmington, Delaware.In a FOX Business exclusive, company CEO Robert Davis told "Mornings with Maria" the effort will take time as Merck builds the capability, but the payoff could mean stable access to drugs in a…
Merck to Invest $1 Billion in U.S. Drug Manufacturing Plant | April 29, 2025
Axios Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing. The move comes amid plans by President Trump to impose tariffs on pharmaceuticals, which would include taxes on imported ingredients used in the making of such medicines. The drug maker on Tuesday announced a new 470,000-square-foot facility in Wilmington, Delaware, where it will make Keytruda, the company’s immunother…
Merck to Invest $1 Billion in U.S. Drug Manufacturing Plant | The Star News Network
Axios Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing. The move comes amid plans by President Trump to impose tariffs on pharmaceuticals, which would include taxes on imported ingredients used in the making of such medicines. The drug maker on Tuesday announced a new 470,000-square-foot facility in Wilmington, Delaware, where it will make Keytruda, the company’s immunother…
Merck Announces $1 Billion Investment in Delaware, 500 Full-Time Jobs
Pharmaceutical company Merck will invest $1 billion to build a 470,000 square-foot facility in Wilmington, Delaware, in a bid to boost domestic production, the company said in an April 29 statement. The facility, located at the Chestnut Run Innovation & Science Park, is expected to create “more than 500 full-time roles and roughly 4,000 construction jobs,” the company said. “The laboratory component is expected to be fully operational by 2028, w…
Coverage Details
Bias Distribution
- 60% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
